NCT06725758
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06725758
Title A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours (TEADES)
Acronym TEADES
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Orion Corporation, Orion Pharma
Indications
Therapies
Age Groups: adult | senior
Covered Countries GBR


No variant requirements are available.